Encore Research

Call us: 904.730.0166

At Risk and Unaware 

Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. According to the Centers for Disease Control and Prevention (CDC), approximately 500,000 Americans are infected with C. diff,[ii] and at least 14,000 fatalities are attributed to C. diff each year.[iii] The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. A main source of C. diff is infected patients who release spores into the environment that can then infect other people. When antibiotics disrupt the gut’s normal flora and a person has ingested C. diff spores, the C. diff bacteria multiply and release potent toxins that can damage a person’s intestinal lining and cause C. diff disease.[iv] 

To see if you might be at risk or to learn more and find out if you or a loved one are eligible to participate in a currently enrolling vaccine trial call: 904-730-0166 or visit: www.jaxresearch.com 

[ii] Rohlke F and Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol. 2012 November; 5(6): 403–420. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491681/#bibr37-1756283X12453637. Accessed May 30, 2013.

[iii] Centers for Disease Control and Prevention. Clostridium difficile Infection. Centers for Disease Control and Prevention. http://www.cdc.gov/hai/organisms/cdiff/cdiff_infect.html. Last Updated March 1, 2013. Accessed May 30, 2013.

[ iv] Delmee M and Warny M. (1995). Clostridium difficile colitis: recent therapeutical and immunological considerations. Acta Gastroenterol Belg, 58 (3-4), p. 313-317.

Posted by Rebecca Plante Thursday, August 13, 2015 9:36:00 AM Categories: Breakthroughs

This is a wonderful time to be a Rheumatologist 

by Steven Mathews, MD

This is a wonderful time to be a Rheumatologist.  Our understanding of the wide scope of immune mediated inflammatory diseases has increased considerably. The intricacies of how inflammation starts, what causes it to increase in intensity and what suppresses that activity are becoming more clear.


When I began my training, the magic answer for treating Rheumatoid Arthritis was gold shots.  The problem with this approach is that it took weekly injections for 5 months to determine if there was going to be a beneficial response.  Of the 20% who did get better with this therapy, only 25 % were still on the medication after the first year due to adverse effects.


The current "gold" standard in RA therapy are the biologics.  These are a collection of medications that target the actual trigger mechanism of our body's inflammatory response.  With these new therapies, the response rate is now 75% in usually less than 12 weeks.  Due to the risk of immunosuppression, we must monitor closely for infections, but very few patients discontinue the medications for safety reasons.  What is even more significant is that approximately 30% of patients reach a point of clinical remission, the goal of any medical therapy.


We at Jacksonville Center for Clinical Research have played a role in this advancement.  We have conducted multiple pivotal studies evaluating not only the efficacy of these medications, but their safety as well.  This has given our patients the opportunity to contribute to the process of evaluating these medications, as well as the chance to benefit from these modalities years before they will be available commercially.  We are currently enrolling for a study which is evaluating the effectiveness of an oral medication, tofacitinib, with and without methotrexate versus a combination of injectable adalimumab, Humira, and methotrexate.


Our involvement in Rheumatology has not been limited to rheumatoid arthritis. We have also been involved with studies evaluating osteoporosis, gout, systemic lupus erythematosus, and osteoarthritis. We are currently looking for patients to participate in a study to evaluate the safety and clinical improvement of tanezumab in patients with osteoarthritis of the hip or knee. This is a new approach to treatment. Tanezumab binds and inhibits the action of nerve growth factor which hopefully will reduce the pain suffered by these patients.


The goal of research is always to advance our knowledge in regards to these very complicated diseases and to develop new effective and safe treatments. We have come a long way towards that goal in the past 20 years, thanks to the patients that have volunteered to participate in these studies. I see more breakthroughs in the future. 

Posted by Amy Autry Bush Monday, July 6, 2015 10:03:00 AM Categories: Breakthroughs
Page 1 of 6 1 2 3 4 5 6 > >>